Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD.
Susan MuiserKai ImkampDianne SeigersNynke J HalbersmaJudith E VonkBart H D LuijkGert-Jan BraunstahlJan-Willem van den BergBart-Jan KroesenJanwillem W H KocksIrene H HeijinkHelen K ReddelHuib A M KerstjensMaarten van den BergePublished in: Thorax (2023)
This first study of MART in COPD found that budesonide/formoterol MART might be similarly effective to fluticasone/salmeterol fixed-dose therapy in moderate to severe patients with COPD, at a lower daily ICS dosage. Further evidence is needed about long-term safety.